Pancreatic Cancer News

Using mRNA tailored to each patient’s tumor, the vaccine may have staved off the return of one of the deadliest forms of cancer in half of those who received it.

In honor of Juneteenth, join us for this important webinar with discussions about clinical trial participation, Health Equity vs. Health Equality, and personal stories from the C-Suite of one of America’s best known cancer centers, along with real progress being made at a local hospital at the epicenter in the fight against cancer.

In the near future, this implantable nanofluidic device could be a game changer in treating pancreatic cancer. Nanomedicine experts at Houston Methodist Academic Institute developed the device. 

The microbiome is a term used for the collection of microbes, including microorganisms like bacteria, that live on or in the human body. Jordan Kharofa, MD, said there was little known about the microbiome of long-term pancreatic cancer survivors.

In an effort to bring new compounds to the pancreatic cancer drug development pipeline, Alec Kimmelman, MD, PhD, a professor in and the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology at NYU Grossman School of Medicine and a member of the senior leadership team at NYU Langone Health’s Perlmutter Cancer Center, has received a […]

Netris Pharma – a company focused on receptor biology – has revealed that the first patient has been dosed during a multi-location, proof-of-concept trial.

Researchers have uncovered an unusual way some cancer cells make nutrients they need to grow, a discovery that could hold the key to starving one of America’s deadliest cancers with a drug we already possess.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Osemitamab (TST001), its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of patients with pancreatic cancer.